A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-27. Anything still debated is marked as such rather than presented as settled.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
On February 4, 2025, United States president Donald Trump proposed a US takeover of the Gaza Strip and the relocation of its Palestinian inhabitants. Officially known as the Gaza Reconstitution, Economic Acceleration and Transformation Trust (or GREAT Trust), the proposal was announced by Trump during a press conference between him and Israeli prime minister Benjamin Netanyahu, and occurred during a ceasefire in the Gaza war, fought between Israel and Hamas-led Palestinian militants. Trump expressed his vision to redevelop the territory into the "Riviera of the Middle East". The proposal called for the forced displacement of approximately two million Palestinians to neighboring lands, and would also have required the removal of over 50 million tonnes of debris and unexploded ordnance. When asked how the territory would be acquired, Trump claimed the US would "take it". The proposal received negative receptions from several nations and organizations, contrasting with strong support from Netanyahu.
The NIA-AA criteria are used mainly in research rather than in clinical assessments. They define AD through three major stages: preclinical, mild cognitive impairment (MCI), and Alzheimer's dementia. Diagnosis in the preclinical stage is complex and focuses on asymptomatic individuals; the latter two stages describe individuals experiencing symptoms, along with biomarkers, predominantly those for neuronal injury (mainly tau-related) and amyloid beta deposition. The core clinical criteria itself rests on the presence of cognitive impairment without the presence of comorbidities. The third stage is divided into probable and possible AD dementia. In probable AD dementia there is steady impairment of cognition over time and a memory-related or non-memory-related cognitive dysfunction. In possible AD dementia, another causal disease such as cerebrovascular disease is present.
=== Critical reviews === "You Hurled Me Into the Depths, Into the Very Heart of the Seas" received mostly positive reviews from critics. Matt Schimkowitz of The A.V. Club gave the episode an "A–" grade and wrote, "Not to be hyperbolic, but tonight's Righteous Gemstones was the funniest 36 minutes in television history. Okay, I won't go that far, but it was a series high. There wasn't a single punchline that didn't hit, a costume choice (or lack thereof) that wasn't a godsend, or a needle drop that was out of place. “You Hurled Me Into the Depths, Into the Very Heart Of The Seas” launches the final season's story out of the deep and finds the production confidently and hilariously ascending toward that big disco ball in the sky." Scott Tobias of Vulture gave the episode a 4 star rating out of 5 and wrote, "As lowbrow laughs go, there's nothing funnier than full-frontal male nudity, and there's certainly no funnier moment than Baby Billy dropping his drawers in front of the Gemstones in the dressing room after their rehearsal goes awry. “Behold, look at this.
==== Sharp criteria ==== The Sharp criteria require at least four major criteria, as well as anti-U1-RNP antibody titer of at least 1:4000, or two major criteria from criteria 1, 2, and 3, and two minor criteria, plus anti-U1-RNP antibody titer of at least 1:1000. The Sharp criteria also excludes anyone with a positive anti-Sm antibody. It has a sensitivity of 42% and a specificity of 87.7%. Major criteria:
According to prosecutor Garzón, Agüero did so as a modus operandi while she visited the resuscitation room with the newborns in her arms. In April 2023, the prosecution added the testimony of the mother of one of the babies who survived the assault. The woman personally accused Agüero and placed her at the side of her baby when the baby decompensated. On 9 August 2023, prosecutor Garzón said that the investigation had entered "its final phase," adding that his office had received reports of two other suspicious deaths of babies. Garzón also said that before going to trial, the prosecution would add more testimonies and witness evidence. On 23 August 2023, the prosecution released the results of the investigation of Agüero's cellphone, where investigators found nine PDF files. Among the nine files, the prosecution said that information was found on how to dose potassium, information related to cardiac arrests, numerous pages of neonatal medications, CPR manuals, and an article on how medical personnel should react to families grieving a newborn. Agüero's defense argued that these files were not downloaded by Agüero herself, but instead, sent to her via WhatsApp. In September 2023, the prosecution added the analysis by a team of criminal profilers who determined that the killings were acts of serial murder and that a single perpetrator was behind them. Without mentioning Agüero, prosecutor Garzón said that the analysis will be a key to the case, because the profilers also pointed to a person with access to the babies and who did not initially raise any suspicion.
Sources: en.wikipedia.org
Large number of compounds of different polarities and chemical properties: EI can offer a shortcut, do-it-all solution when hard-to-detect substances are included or and when a combination of positive and negative ion detection runs are required for complete coverage of analyte detection. Characterization of unknowns: library matching offer an invaluable tool for compound identification. Detection of non chromophoric compounds that also give poor or no signal with API: for these compounds additional HPLC detectors such as evaporative light scattering detector (ELSD), refractive index (RI) or corona discharge aerosol detector (CAD) are also available but each of them has limitations which restrain obtaining a universal detection with reasonable sensitivity. EI-MS would offer a suitable solution for this type of compounds, in terms of sensitivity and universal response. GC is anyway feasible only for compounds with high to medium volatility and therefore cannot be adopted for a full characterization of mixtures of complex nature. The possibility of hyphenating EI to HPLC separation represents an ideal solution. Quantitative analyses in presence of matrix effects: EI-MS offers a superior performance compared to ESI or APCI when intruding interferences from complex matrices pass cleanup procedure and cause signal suppression or enhancement.
== Composition == The PDL substance has been estimated to be 70% water, which is thought to have a significant effect on the tooth's ability to withstand stress loads. The completeness and vitality of the PDL are essential for the functioning of the tooth. The PDL ranges in width from 0.15 to 0.38mm with its thinnest part located in the middle third of the root. The width progressively decreases with age. The PDL is a part of the periodontium that provides for the attachment of the teeth to the surrounding alveolar bone by way of the cementum. The PDL appears as the periodontal space of 0.4 to 1.5 mm on radiographs, a radiolucent area between the radiopaque lamina dura of the alveolar bone proper and the radiopaque cementum.
Whey protein is a mixture of proteins isolated from whey, the liquid material created as a by-product of cheese production. The proteins consist of α-lactalbumin, β-lactoglobulin, serum albumin and immunoglobulins. Glycomacropeptide also makes up the third largest component but is not a protein. Whey protein is commonly marketed as a protein supplement.
== Awards and honors == Machine Learning in the Chemical Sciences & Engineering Award, Camille and Henry Dreyfus Foundation, 2020 2015: OpenEye Outstanding Junior Faculty Award in Computational Chemistry, American Chemical Society
In chemistry, sparging, also known as gas flushing in metallurgy, is a technique in which a gas is bubbled through a liquid in order to remove other dissolved gas(es) and/or dissolved volatile liquid(s) from that liquid. It is a method of degassing. According to Henry's law, the concentration of each gas in a liquid is proportional to the partial pressure of that gas (in the gaseous state) in contact with the liquid. Sparging introduces a gas that has little or no partial pressure of the gas(es) to be removed, and increases the area of the gas-liquid interface, which encourages some of the dissolved gas(es) to diffuse into the sparging gas before the sparging gas escapes from the liquid. Many sparging processes, such as solvent removal, use air as the sparging gas. To remove oxygen, or for sensitive solutions or reactive molten metals, a chemically inert gas such as nitrogen, argon, or helium is used.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.